Apollomics Inc. (NASDAQ:APLM) Short Interest Down 30.9% in March

Apollomics Inc. (NASDAQ:APLM) saw a significant decline in short interest in March. As of March 13th, there was short interest totaling 8,621 shares, a decline of 30.9% from the February 26th total of 12,471 shares. Based on an average daily volume of 7,156 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.8% of the shares of the stock are sold short.

Institutional Trading of Apollomics

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC purchased a new stake in shares of Apollomics Inc. (NASDAQ:APLM) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics at the end of the most recent reporting period. Institutional investors own 19.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on APLM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apollomics in a research note on Monday, December 29th. Wall Street Zen raised shares of Apollomics from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Apollomics has an average rating of “Sell”.

Apollomics Trading Up 0.1%

APLM opened at $17.65 on Friday. The stock has a 50-day moving average price of $19.51 and a 200-day moving average price of $18.60. Apollomics has a 12-month low of $3.66 and a 12-month high of $42.12.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.